North America Legal Cannabis Market Size, Share & Trends Analysis Report By Source (Marijuana, Hemp), By End-use (Recreational, Industrial, Medical Uses), By Derivative (CBD, THC), And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 3 Business Days
North America Legal Cannabis Market Growth & Trends
The North America legal cannabis market size is expected to hit USD 47.5 billion by 2030, registering a CAGR of 15.3% from 2022 to 2030, as per a new report by Grand View Research, Inc. The market is likely to see a marginal increase in demand due to the changing government policies for product legalization and use. Off-late, the population across North America has been made aware of the benefits entailing the use of cannabis for multiple indications. Many start-ups and the federal & private organizations are taking up research and production activities of cannabis-infused products and derivatives, which is further going to propel the market growth.
The use of cannabis has been more prevalent in the form of dried flowers and buds, up until its legalization, it was sold as an illicit drug across North America due to its psychoactive properties and addictive nature. The product usage in medicine is being propelled by the fact that in most products, THC, the compound present in cannabis, responsible for its psychoactive properties, is often omitted or is present in trace amounts. It is still a federally illegal drug but has been legalized in small amounts, majorly for use as medicine for the treatment of chronic pain, neurological conditions, etc. This has been a key factor in the growth of the market as well as a reason behind the vast rate of legitimization of the drug across the region.
Cultivation and production of cannabis and related products have also had a huge economic impact on the region’s economy. In 2021, the U.S. collected USD 3.7 billion in tax revenues for legal cannabis, which was almost twice what it was in 2019. Its legalization is bound to create more jobs, and income for cultivators, manufacturers, etc., and developing interest in the industry has also led to an increase in the number of organizations wanting to invest, thereby propelling the market growth. The marijuana source type segment held the largest market share in 2021. Marijuana consisting of flowers, oils, and tinctures has been used extensively in the region for decades.
It has also been decriminalized and is legal in the majority of the states across the U.S. and Canada, which has contributed to the high revenue share of the segment. It has also been legalized for recreational use in a number of states which has contributed significantly to increasing sales, resulting in the fast growth of the segment as well. Cannabidiol (CBD) as a derivative is being extensively used for medications in various indications including, epileptic seizures, chronic pain, and nausea induced by chemotherapy along with many others making it the highest share-holding category in the derivatives segment. Cannabidiol became legal in 2018, and since then it has been used in making medicines, ointments, etc. for various indications.
The other derivatives segment is estimated to register the fastest CAGR from 2022 to 2030. The others segment includes minor cannabinoids, terpenes, and flavonoids, which are used for their benefits for multiple indications. The medical end-use segment held the largest share of the overall revenue in 2021. Cannabis has been legalized in more than 30 states for use in medicinal preparations. The recreational use segment is estimated to record the fastest CAGR from 2022 to 2030. In 2020 and 2021, since its legalization for recreational purposes, it is now being sold over the counter at dedicated stores, thus has been responsible for the overall market growth.
The production and processing of cannabis-derived goods in the U.S., the presence of a huge pool of health-conscious consumers, and the presence of significant manufacturers in the region are propelling the industry growth. In addition, the COVID-19 pandemic had an adverse impact on the market. Several dispensaries, such as Bud and Bloom, had a 30.0% surge in weekly sales, according to the Orange County Register, on March 17, 2020. In February 2022, Groff North America, a federally, legal producer of cannabis, gained multiple schedule I registrations from the DEA, including bulk manufacturing, non-bulk manufacturing, exporter, researcher as well as the analytical lab. This is a major step for the regional market.
North America Legal Cannabis Market Report Highlights
North America Legal Cannabis Market Growth & Trends
The North America legal cannabis market size is expected to hit USD 47.5 billion by 2030, registering a CAGR of 15.3% from 2022 to 2030, as per a new report by Grand View Research, Inc. The market is likely to see a marginal increase in demand due to the changing government policies for product legalization and use. Off-late, the population across North America has been made aware of the benefits entailing the use of cannabis for multiple indications. Many start-ups and the federal & private organizations are taking up research and production activities of cannabis-infused products and derivatives, which is further going to propel the market growth.
The use of cannabis has been more prevalent in the form of dried flowers and buds, up until its legalization, it was sold as an illicit drug across North America due to its psychoactive properties and addictive nature. The product usage in medicine is being propelled by the fact that in most products, THC, the compound present in cannabis, responsible for its psychoactive properties, is often omitted or is present in trace amounts. It is still a federally illegal drug but has been legalized in small amounts, majorly for use as medicine for the treatment of chronic pain, neurological conditions, etc. This has been a key factor in the growth of the market as well as a reason behind the vast rate of legitimization of the drug across the region.
Cultivation and production of cannabis and related products have also had a huge economic impact on the region’s economy. In 2021, the U.S. collected USD 3.7 billion in tax revenues for legal cannabis, which was almost twice what it was in 2019. Its legalization is bound to create more jobs, and income for cultivators, manufacturers, etc., and developing interest in the industry has also led to an increase in the number of organizations wanting to invest, thereby propelling the market growth. The marijuana source type segment held the largest market share in 2021. Marijuana consisting of flowers, oils, and tinctures has been used extensively in the region for decades.
It has also been decriminalized and is legal in the majority of the states across the U.S. and Canada, which has contributed to the high revenue share of the segment. It has also been legalized for recreational use in a number of states which has contributed significantly to increasing sales, resulting in the fast growth of the segment as well. Cannabidiol (CBD) as a derivative is being extensively used for medications in various indications including, epileptic seizures, chronic pain, and nausea induced by chemotherapy along with many others making it the highest share-holding category in the derivatives segment. Cannabidiol became legal in 2018, and since then it has been used in making medicines, ointments, etc. for various indications.
The other derivatives segment is estimated to register the fastest CAGR from 2022 to 2030. The others segment includes minor cannabinoids, terpenes, and flavonoids, which are used for their benefits for multiple indications. The medical end-use segment held the largest share of the overall revenue in 2021. Cannabis has been legalized in more than 30 states for use in medicinal preparations. The recreational use segment is estimated to record the fastest CAGR from 2022 to 2030. In 2020 and 2021, since its legalization for recreational purposes, it is now being sold over the counter at dedicated stores, thus has been responsible for the overall market growth.
The production and processing of cannabis-derived goods in the U.S., the presence of a huge pool of health-conscious consumers, and the presence of significant manufacturers in the region are propelling the industry growth. In addition, the COVID-19 pandemic had an adverse impact on the market. Several dispensaries, such as Bud and Bloom, had a 30.0% surge in weekly sales, according to the Orange County Register, on March 17, 2020. In February 2022, Groff North America, a federally, legal producer of cannabis, gained multiple schedule I registrations from the DEA, including bulk manufacturing, non-bulk manufacturing, exporter, researcher as well as the analytical lab. This is a major step for the regional market.
North America Legal Cannabis Market Report Highlights
- The market will grow at a significant rate due to increasing product legalization and rising awareness among consumers about the health benefits of the product
- The marijuana source type segment led the market in 2021 due to the increased legalization and its usage for medical purposes
- The CBD derivatives segment dominated the market in 2021 due to the increased use of CBD for various medical applications and awareness about CBD’s effectiveness in the treatment of various medical diseases
- The recreational end-use segment held the largest revenue share in 2021 due to increased use of cannabis for recreational purposes and high awareness regarding cannabis usage
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Research Process
1.2 Information Procurement
1.2.1 Purchased database
1.2.1.1 GVR’s internal database
1.2.2 Market Formulation & Validation
1.3 Research Methodology
1.4 Research Scope And Assumptions
1.5 Research Methodology
1.5.1 Region Market: CAGR Calculation
1.5.1.1 Region Based Segment Share Calculation
1.6 List To Data Sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Summary
CHAPTER 3 NORTH AMERICA LEGAL CANNABIS MARKET: VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Growing adoption of medical marijuana for treatment of chronic diseases
3.3.1.2 Elimination of black market through the legalization of medical marijuana
3.3.2 Market Restraint Analysis
3.3.2.1 High pricing of cannabis compared to illegal markets in the U.S.
3.3.2.2 Illicit cannabis trade due to surplus cultivation
3.4 Industry Analysis - SWOT Analysis, By Factor (Political & Legal, Economic, And Technological
3.4.1 Political And Legal Landscape
3.4.2 Economic And Social Landscape
3.4.3 Technology Landscape
3.5 Cannabis Market - Porter’s Analysis
3.5.1. Threat of New Entrants
3.5.2 Bargaining Power of Buyers
3.5.3 Competitive Rivalry
3.5.4 Bargaining Power of Suppliers
3.5.5 Threat of Substitutes
3.6 History of Medical Use of Cannabis in North America
3.7 History of Industrial Use of Cannabis in North America
3.8 North America Legal Cannabis Number of clinical trials
3.9 Legal Cannabis Industry: Legalization Timeline in North America
3.9.1 Legalization Landscape (Timeline)
3.9.2 The U.S. Legalization Landscape
3.9.3 The Canada Legalization Landscape
3.9.4 North America Legal Cannabis Regulatory Scenario, By Country
3.9.4.1 U.S.
3.9.4.1.1 Overview
3.9.4.1.2 Cultivation/Production
3.9.4.1.3 Regulatory Bodies Involved
3.9.4.2 Canada
3.9.4.2.1 Overview
3.9.4.2.2 Cultivation
3.9.4.2.3 Production
3.9.4.2.4 Regulatory Bodies Involved
3.10 North America Legal Cannabis Industry: Consumption Pattern Analysis
3.10.1 North America
3.11 Trade Opportunity Analysis, by region
3.11.1 North America
3.12 Legal Cannabis Industry: Country Case Study
3.12.1 U.S.
3.12.1.1 Legalization of Cannabis
3.12.1.2 Reason for Legalization
3.12.1.3 Scenario After Legalization and Consumer Attitude
3.12.1.4 Competitive Landscape Post Legalization
3.12.2 Canada
3.12.2.1 Legalization of Cannabis
3.12.2.2 Reason for Legalization
3.12.2.3 Scenario After Legalization
3.12.2.4 Consumer Attitudes Toward Legalization
3.12.2.5 Competitive Landscape Post Legalization:
3.13 Human Abuse Liability Experience in North America Cannabis Market
3.14 Qualitative analysis on synthetic cannabinoids and cannabis in North America
CHAPTER 4 NORTH AMERICA LEGAL CANNABIS MARKET: SOURCE ESTIMATES & TREND ANALYSIS
4.1 North America Legal Cannabis Market: Source Movement Analysis
4.2 North America Legal Cannabis Market: Source Analysis
4.2.1 Hemp
4.2.1.1 Hemp Market Estimates and Forecasts, 2017 - 2030 (USD Million)
4.2.1.2 Hemp CBD
4.2.1.2.1 Hemp CBD Market Estimates and Forecasts, 2017 - 2030 (USD Million)
4.2.1.3 Supplements
4.2.1.3.1 Supplements Market Estimates and Forecasts, 2017 - 2030 (USD Million)
4.2.1.4 Industrial Hemp
4.2.1.4.1 Industrial Hemp Market Estimates and Forecasts, 2017 - 2030 (USD Million)
4.2.2 Marijuana
4.2.2.1 Marijuana Market Estimates and Forecasts, 2017 - 2030 (USD Million)
4.2.2.2 Flower
4.2.2.2.1 Flower Market Estimates and Forecasts, 2017 - 2030 (USD Million)
4.2.2.3 Oils and Tinctures
4.2.2.3.1 Oils and Tinctures Market Estimates and Forecasts, 2017 - 2030 (USD Million)
CHAPTER 5 NORTH AMERICA LEGAL CANNABIS MARKET: DERIVATIVES ESTIMATES & TREND ANALYSIS
5.1 North America Legal Cannabis Market: Derivatives Movement Analysis
5.2 North America Legal Cannabis Market: Derivatives Analysis
5.2.1 CBD
5.2.1.1 CBD Market Estimates and Forecasts, 2017 - 2030 (USD Million)
5.2.2 THC
5.2.2.1 THC Market Estimates and Forecasts, 2017 - 2030 (USD Million)
5.2.3 Others
5.2.3.1 Others Market Estimates and Forecasts, 2017 - 2030 (USD Million)
CHAPTER 6 NORTH AMERICA LEGAL CANNABIS MARKET: END-USE ESTIMATES & TREND ANALYSIS
6.1 North America Legal Cannabis Market: End Use Movement Analysis
6.2 North America Legal Cannabis Market: End Use Analysis
6.2.1 Recreational Use
6.2.1.1 Recreational Use Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2 Medical Use
6.2.2.1 Medical Use Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.2 Chronic Pain
6.2.2.2.1 Chronic Pain Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.3 Cancer
6.2.2.3.1 Chemotherapy-Induced Nausea & Vomiting
6.2.2.3.2 Cancer Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.4 Depression and Anxiety
6.2.2.4.1 Depression and Anxiety Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.5 Arthritis
6.2.2.5.1 Arthritis Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.6 Diabetes
6.2.2.6.1 Diabetes Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.7 Glaucoma
6.2.2.7.1 Glaucoma Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.8 Migraines
6.2.2.8.1 Migraines Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.9 Epilepsy
6.2.2.9.1 Epilepsy Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.10 Multiple Sclerosis
6.2.2.10.1 Multiple Sclerosis Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.11 AIDS
6.2.2.11.1 AIDS Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.12 Amyotrophic Lateral Sclerosis (ALS)
6.2.2.12.1 ALS Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.13 Alzheimer’s
6.2.2.13.1 Alzheimer’s Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.14 Post Traumatic Stress Disorder (PTSD)
6.2.2.14.1 PTSD Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.15 Parkinson’s
6.2.2.15.1 Parkinson’s Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.16 Tourette’s
6.2.2.16.1 Tourette’s Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.17 Others
6.2.2.17.1 Others Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.3 Industrial Use
6.2.3.1 Industrial Use Market Estimates and Forecasts, 2017 - 2030 (USD Million)
CHAPTER 7 NORTH AMERICA LEGAL CANNABIS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1 North America Legal Cannabis Market: Region Movement Analysis, 2017 - 2030
7.1.1. North America
7.1.1.1 North America Legal Cannabis Market Estimates and Forecasts, 2017 - 2030 (USD Million)
7.1.2 U.S.
7.1.2.1 U.S. Legal Cannabis Market Estimates and Forecasts, 2017 - 2030 (USD Million)
7.1.3 Canada
7.1.3.1 Canada Legal Cannabis Market Estimates and Forecasts, 2017 - 2030 (USD Million)
CHAPTER 8 COMPETITIVE ANALYSIS
8.1 Company Market Position Analysis
8.2 Recent Developments & Impact Analysis, By Key Market Participants
8.3 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
8.4 List of Tobacco Companies Investing in Cannabis
CHAPTER 9 COMPETITIVE LANDSCAPE
9.1 Major Companies in The Ecosystem, By Various Parameters
9.1.1 Canopy Growth Corporation
9.1.2 GW Pharmaceuticals, plc
9.1.3 Aurora Cannabis
9.1.4 Aphria, Inc. (Prior to the merger with Tilray)
9.1.5 Cronos Group
9.1.6 Tilray
9.1.7 Sundial Growers
9.1.8 Insys Therapeutics, Inc.
9.1.9 Vivo Cannabis Inc.
9.1.10 Cara Therapeutics, Inc
1.1 Research Process
1.2 Information Procurement
1.2.1 Purchased database
1.2.1.1 GVR’s internal database
1.2.2 Market Formulation & Validation
1.3 Research Methodology
1.4 Research Scope And Assumptions
1.5 Research Methodology
1.5.1 Region Market: CAGR Calculation
1.5.1.1 Region Based Segment Share Calculation
1.6 List To Data Sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Summary
CHAPTER 3 NORTH AMERICA LEGAL CANNABIS MARKET: VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Growing adoption of medical marijuana for treatment of chronic diseases
3.3.1.2 Elimination of black market through the legalization of medical marijuana
3.3.2 Market Restraint Analysis
3.3.2.1 High pricing of cannabis compared to illegal markets in the U.S.
3.3.2.2 Illicit cannabis trade due to surplus cultivation
3.4 Industry Analysis - SWOT Analysis, By Factor (Political & Legal, Economic, And Technological
3.4.1 Political And Legal Landscape
3.4.2 Economic And Social Landscape
3.4.3 Technology Landscape
3.5 Cannabis Market - Porter’s Analysis
3.5.1. Threat of New Entrants
3.5.2 Bargaining Power of Buyers
3.5.3 Competitive Rivalry
3.5.4 Bargaining Power of Suppliers
3.5.5 Threat of Substitutes
3.6 History of Medical Use of Cannabis in North America
3.7 History of Industrial Use of Cannabis in North America
3.8 North America Legal Cannabis Number of clinical trials
3.9 Legal Cannabis Industry: Legalization Timeline in North America
3.9.1 Legalization Landscape (Timeline)
3.9.2 The U.S. Legalization Landscape
3.9.3 The Canada Legalization Landscape
3.9.4 North America Legal Cannabis Regulatory Scenario, By Country
3.9.4.1 U.S.
3.9.4.1.1 Overview
3.9.4.1.2 Cultivation/Production
3.9.4.1.3 Regulatory Bodies Involved
3.9.4.2 Canada
3.9.4.2.1 Overview
3.9.4.2.2 Cultivation
3.9.4.2.3 Production
3.9.4.2.4 Regulatory Bodies Involved
3.10 North America Legal Cannabis Industry: Consumption Pattern Analysis
3.10.1 North America
3.11 Trade Opportunity Analysis, by region
3.11.1 North America
3.12 Legal Cannabis Industry: Country Case Study
3.12.1 U.S.
3.12.1.1 Legalization of Cannabis
3.12.1.2 Reason for Legalization
3.12.1.3 Scenario After Legalization and Consumer Attitude
3.12.1.4 Competitive Landscape Post Legalization
3.12.2 Canada
3.12.2.1 Legalization of Cannabis
3.12.2.2 Reason for Legalization
3.12.2.3 Scenario After Legalization
3.12.2.4 Consumer Attitudes Toward Legalization
3.12.2.5 Competitive Landscape Post Legalization:
3.13 Human Abuse Liability Experience in North America Cannabis Market
3.14 Qualitative analysis on synthetic cannabinoids and cannabis in North America
CHAPTER 4 NORTH AMERICA LEGAL CANNABIS MARKET: SOURCE ESTIMATES & TREND ANALYSIS
4.1 North America Legal Cannabis Market: Source Movement Analysis
4.2 North America Legal Cannabis Market: Source Analysis
4.2.1 Hemp
4.2.1.1 Hemp Market Estimates and Forecasts, 2017 - 2030 (USD Million)
4.2.1.2 Hemp CBD
4.2.1.2.1 Hemp CBD Market Estimates and Forecasts, 2017 - 2030 (USD Million)
4.2.1.3 Supplements
4.2.1.3.1 Supplements Market Estimates and Forecasts, 2017 - 2030 (USD Million)
4.2.1.4 Industrial Hemp
4.2.1.4.1 Industrial Hemp Market Estimates and Forecasts, 2017 - 2030 (USD Million)
4.2.2 Marijuana
4.2.2.1 Marijuana Market Estimates and Forecasts, 2017 - 2030 (USD Million)
4.2.2.2 Flower
4.2.2.2.1 Flower Market Estimates and Forecasts, 2017 - 2030 (USD Million)
4.2.2.3 Oils and Tinctures
4.2.2.3.1 Oils and Tinctures Market Estimates and Forecasts, 2017 - 2030 (USD Million)
CHAPTER 5 NORTH AMERICA LEGAL CANNABIS MARKET: DERIVATIVES ESTIMATES & TREND ANALYSIS
5.1 North America Legal Cannabis Market: Derivatives Movement Analysis
5.2 North America Legal Cannabis Market: Derivatives Analysis
5.2.1 CBD
5.2.1.1 CBD Market Estimates and Forecasts, 2017 - 2030 (USD Million)
5.2.2 THC
5.2.2.1 THC Market Estimates and Forecasts, 2017 - 2030 (USD Million)
5.2.3 Others
5.2.3.1 Others Market Estimates and Forecasts, 2017 - 2030 (USD Million)
CHAPTER 6 NORTH AMERICA LEGAL CANNABIS MARKET: END-USE ESTIMATES & TREND ANALYSIS
6.1 North America Legal Cannabis Market: End Use Movement Analysis
6.2 North America Legal Cannabis Market: End Use Analysis
6.2.1 Recreational Use
6.2.1.1 Recreational Use Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2 Medical Use
6.2.2.1 Medical Use Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.2 Chronic Pain
6.2.2.2.1 Chronic Pain Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.3 Cancer
6.2.2.3.1 Chemotherapy-Induced Nausea & Vomiting
6.2.2.3.2 Cancer Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.4 Depression and Anxiety
6.2.2.4.1 Depression and Anxiety Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.5 Arthritis
6.2.2.5.1 Arthritis Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.6 Diabetes
6.2.2.6.1 Diabetes Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.7 Glaucoma
6.2.2.7.1 Glaucoma Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.8 Migraines
6.2.2.8.1 Migraines Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.9 Epilepsy
6.2.2.9.1 Epilepsy Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.10 Multiple Sclerosis
6.2.2.10.1 Multiple Sclerosis Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.11 AIDS
6.2.2.11.1 AIDS Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.12 Amyotrophic Lateral Sclerosis (ALS)
6.2.2.12.1 ALS Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.13 Alzheimer’s
6.2.2.13.1 Alzheimer’s Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.14 Post Traumatic Stress Disorder (PTSD)
6.2.2.14.1 PTSD Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.15 Parkinson’s
6.2.2.15.1 Parkinson’s Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.16 Tourette’s
6.2.2.16.1 Tourette’s Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.2.17 Others
6.2.2.17.1 Others Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.2.3 Industrial Use
6.2.3.1 Industrial Use Market Estimates and Forecasts, 2017 - 2030 (USD Million)
CHAPTER 7 NORTH AMERICA LEGAL CANNABIS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1 North America Legal Cannabis Market: Region Movement Analysis, 2017 - 2030
7.1.1. North America
7.1.1.1 North America Legal Cannabis Market Estimates and Forecasts, 2017 - 2030 (USD Million)
7.1.2 U.S.
7.1.2.1 U.S. Legal Cannabis Market Estimates and Forecasts, 2017 - 2030 (USD Million)
7.1.3 Canada
7.1.3.1 Canada Legal Cannabis Market Estimates and Forecasts, 2017 - 2030 (USD Million)
CHAPTER 8 COMPETITIVE ANALYSIS
8.1 Company Market Position Analysis
8.2 Recent Developments & Impact Analysis, By Key Market Participants
8.3 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
8.4 List of Tobacco Companies Investing in Cannabis
CHAPTER 9 COMPETITIVE LANDSCAPE
9.1 Major Companies in The Ecosystem, By Various Parameters
9.1.1 Canopy Growth Corporation
9.1.2 GW Pharmaceuticals, plc
9.1.3 Aurora Cannabis
9.1.4 Aphria, Inc. (Prior to the merger with Tilray)
9.1.5 Cronos Group
9.1.6 Tilray
9.1.7 Sundial Growers
9.1.8 Insys Therapeutics, Inc.
9.1.9 Vivo Cannabis Inc.
9.1.10 Cara Therapeutics, Inc
LIST OF TABLES
TABLE 1 Major companies in the ecosystem, by funding, number of employees, headquarters, and business model
TABLE 2 Major companies in the ecosystem, by revenue, net loss, valuation, regions, etc.
TABLE 3 North America legal cannabis market, by country, 2017 - 2030 (USD Million)
TABLE 4 North America legal cannabis market, by sources, 2017 - 2030 (USD Million)
TABLE 5 North America legal marijuana market, by product, 2017 - 2030 (USD Million)
TABLE 6 North America hemp market, by product, 2017 - 2030 (USD Million)
TABLE 7 North America legal cannabis market, by derivatives, 2017 - 2030 (USD Million)
TABLE 8 North America legal cannabis market, by end-use, 2017 – 2030 (USD Million)
TABLE 9 North America medical-use market, by medical condition, 2017 - 2030 (USD Million)
TABLE 10 U.S. legal cannabis market, by sources, 2017 - 2030 (USD Million)
TABLE 11 U.S. legal marijuana market, by product, 2017 - 2030 (USD Million)
TABLE 12 U.S. hemp market, by product, 2017 - 2030 (USD Million)
TABLE 13 U.S. legal cannabis market, by derivatives, 2017 - 2030 (USD Million)
TABLE 14 U.S. legal cannabis market, by end-use, 2017 - 2030 (USD Million)
TABLE 15 U.S. medical-use market, by medical condition, 2017 - 2030 (USD Million)
TABLE 16 Canada legal cannabis market, by sources, 2017 - 2030 (USD Million)
TABLE 17 Canada legal marijuana market, by product, 2017 - 2030 (USD Million)
TABLE 18 Canada hemp market, by product, 2017 - 2030 (USD Million)
TABLE 19 Canada legal cannabis market, by derivatives, 2017 - 2030 (USD Million
TABLE 20 Canada legal cannabis market, by end-use, 2017 - 2030 (USD Million)
TABLE 21 Canada medical-use market, by medical condition, 2017 - 2030 (USD Million)
TABLE 1 Major companies in the ecosystem, by funding, number of employees, headquarters, and business model
TABLE 2 Major companies in the ecosystem, by revenue, net loss, valuation, regions, etc.
TABLE 3 North America legal cannabis market, by country, 2017 - 2030 (USD Million)
TABLE 4 North America legal cannabis market, by sources, 2017 - 2030 (USD Million)
TABLE 5 North America legal marijuana market, by product, 2017 - 2030 (USD Million)
TABLE 6 North America hemp market, by product, 2017 - 2030 (USD Million)
TABLE 7 North America legal cannabis market, by derivatives, 2017 - 2030 (USD Million)
TABLE 8 North America legal cannabis market, by end-use, 2017 – 2030 (USD Million)
TABLE 9 North America medical-use market, by medical condition, 2017 - 2030 (USD Million)
TABLE 10 U.S. legal cannabis market, by sources, 2017 - 2030 (USD Million)
TABLE 11 U.S. legal marijuana market, by product, 2017 - 2030 (USD Million)
TABLE 12 U.S. hemp market, by product, 2017 - 2030 (USD Million)
TABLE 13 U.S. legal cannabis market, by derivatives, 2017 - 2030 (USD Million)
TABLE 14 U.S. legal cannabis market, by end-use, 2017 - 2030 (USD Million)
TABLE 15 U.S. medical-use market, by medical condition, 2017 - 2030 (USD Million)
TABLE 16 Canada legal cannabis market, by sources, 2017 - 2030 (USD Million)
TABLE 17 Canada legal marijuana market, by product, 2017 - 2030 (USD Million)
TABLE 18 Canada hemp market, by product, 2017 - 2030 (USD Million)
TABLE 19 Canada legal cannabis market, by derivatives, 2017 - 2030 (USD Million
TABLE 20 Canada legal cannabis market, by end-use, 2017 - 2030 (USD Million)
TABLE 21 Canada medical-use market, by medical condition, 2017 - 2030 (USD Million)
LIST OF FIGURES
FIG. 1 Various stages of the research workflow
FIG. 2 Information procurement
FIG. 3 Market Formulation & Validation
FIG. 4 North America Legal Cannabis Market snapshot, 2021 (USD Million)
FIG. 5 North America Legal Cannabis Market segmentation
FIG. 6 Penetration & growth prospect mapping for end-use type, 2021
FIG. 7 Market driver relevance analysis (Current & future impact)
FIG. 8 North America Legal Cannabis Market restraints impact
FIG. 9 Number of clinical trials, by country
FIG. 10 The state-wise legalization scenario in the U.S
FIG. 11 Consumption of cannabis oil for oral use
FIG. 12 Percentage of respondents using cannabis edible products and those using products other than edibles
FIG. 13 North America Legal Cannabis Market, source type outlook: Key takeaways
FIG. 14 North America Legal Cannabis Market: source type movement analysis (2021 & 2030) (USD Million)
FIG. 15 Hemp market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 16 Hemp CBD market estimates and forecasts, 2017 - 2030 (USD Million
FIG. 17 Supplements market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 18 Industrial hemp market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 19 Marijuana market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 20 Flower market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 21 Oil and tinctures market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 22 North America Legal Cannabis Market, derivatives outlook: Key takeaways
FIG. 23 North America Legal Cannabis Market: derivatives type movement analysis (2021 & 2030) (USD Million)
FIG. 24 CBD market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 25 THC market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 26 Others market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 27 North America Legal Cannabis Market, end-use outlook: Key takeaways
FIG. 28 North America Legal Cannabis Market: End-use movement analysis (2020 & 2030)
FIG. 29 Recreational use market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 30 Medical use market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 31 Chronic pain market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 32 Cancer market estimates and forecasts, 2017 - 2028 (USD Million)
FIG. 33 Depression and anxiety market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 34 Arthritis market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 35 Diabetes market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 36 Glaucoma market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 37 Migraines market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 38 Epilepsy market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 39 Multiple Sclerosis market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 40 AIDS market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 41 ALS market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 42 Alzheimer’s market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 43 PTSD market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 44 Parkinson’s market estimates and forecasts, 2017 – 2030 (USD Million)
FIG. 45 Tourette’s market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 46 Others market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 47 Industrial use market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 48 Regional marketplace: Key takeaways
FIG. 49 North America Legal Cannabis Market: Regional movement analysis (2021 & 2030)
FIG. 50 North America Legal Cannabis Market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 51 U.S. Legal Cannabis Market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 52 Canada Legal Cannabis Market estimates and forecasts, 2017 - 2030 (USD million)
FIG. 53 Company market position analysis
FIG. 54 Recent Developments & Impact Analysis, By Key Market Participants
FIG. 1 Various stages of the research workflow
FIG. 2 Information procurement
FIG. 3 Market Formulation & Validation
FIG. 4 North America Legal Cannabis Market snapshot, 2021 (USD Million)
FIG. 5 North America Legal Cannabis Market segmentation
FIG. 6 Penetration & growth prospect mapping for end-use type, 2021
FIG. 7 Market driver relevance analysis (Current & future impact)
FIG. 8 North America Legal Cannabis Market restraints impact
FIG. 9 Number of clinical trials, by country
FIG. 10 The state-wise legalization scenario in the U.S
FIG. 11 Consumption of cannabis oil for oral use
FIG. 12 Percentage of respondents using cannabis edible products and those using products other than edibles
FIG. 13 North America Legal Cannabis Market, source type outlook: Key takeaways
FIG. 14 North America Legal Cannabis Market: source type movement analysis (2021 & 2030) (USD Million)
FIG. 15 Hemp market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 16 Hemp CBD market estimates and forecasts, 2017 - 2030 (USD Million
FIG. 17 Supplements market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 18 Industrial hemp market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 19 Marijuana market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 20 Flower market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 21 Oil and tinctures market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 22 North America Legal Cannabis Market, derivatives outlook: Key takeaways
FIG. 23 North America Legal Cannabis Market: derivatives type movement analysis (2021 & 2030) (USD Million)
FIG. 24 CBD market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 25 THC market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 26 Others market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 27 North America Legal Cannabis Market, end-use outlook: Key takeaways
FIG. 28 North America Legal Cannabis Market: End-use movement analysis (2020 & 2030)
FIG. 29 Recreational use market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 30 Medical use market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 31 Chronic pain market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 32 Cancer market estimates and forecasts, 2017 - 2028 (USD Million)
FIG. 33 Depression and anxiety market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 34 Arthritis market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 35 Diabetes market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 36 Glaucoma market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 37 Migraines market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 38 Epilepsy market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 39 Multiple Sclerosis market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 40 AIDS market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 41 ALS market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 42 Alzheimer’s market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 43 PTSD market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 44 Parkinson’s market estimates and forecasts, 2017 – 2030 (USD Million)
FIG. 45 Tourette’s market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 46 Others market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 47 Industrial use market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 48 Regional marketplace: Key takeaways
FIG. 49 North America Legal Cannabis Market: Regional movement analysis (2021 & 2030)
FIG. 50 North America Legal Cannabis Market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 51 U.S. Legal Cannabis Market estimates and forecasts, 2017 - 2030 (USD Million)
FIG. 52 Canada Legal Cannabis Market estimates and forecasts, 2017 - 2030 (USD million)
FIG. 53 Company market position analysis
FIG. 54 Recent Developments & Impact Analysis, By Key Market Participants
